Document Type : Original Article
Authors
1 دانشگاه علوم پزشکی سبزوار
2 هیئت علمی
3 Department of Social Medicine, Faculty of Medicine, Sabzevar University of Medical Sciences, Khorasan Razavi, Iran PhD student in medical education, Department of Medical Education, Faculty of Medicine, Shiraz University of Medical Sciences, Iran
Abstract
Background and objective: Olanzapine is one of the antipsychotic drugs for the treatment of schizophrenia, but it has been noticed due to significant metabolic adverse effects, including the highest weight gain among all antipsychotic drugs.
Materials and methods: This study was conducted as a clinical trial on 120 patients with psychosis under standard treatment with olanzapine. The weight and waist circumference of both groups were measured before and after the study, and the effect of betahistine on the intervention group was compared to the control group. The study data were transformed using SPSS version 24 software and using statistical methods of analysis.
findings:
. The weight before the intervention in the control group was 66.3±10.88, and after the intervention it was 69.67±13.03, and in the intervention group, before the start of the study, it was 66.45±9.95 and after the intervention, it was 11.20. Waist circumference 68.16 ± 70.06 cm ± 12.63 ± 12.63 cm before the intervention in the control group and 71.55 ± 13.13 cm after the intervention and in the intervention group the waist circumference was 11.80 ± 11.80 cm. ± 68.26 cm and after the end of the intervention, 69.4 ± 12.70 cm was obtained.
Conclusion: At the same time as weight gain, olanzapine is prevented in the intervention group and there was no method to prevent weight gain caused by olanzapine.
Keywords
Main Subjects
)